April 10, 2026Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026Read article
March 17, 2026Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026Read article
March 12, 2026Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent HighlightsRead article